2. Disease Areas
  3. Urogenital Disease
  4. Urologic Disease

Urologic Disease

Urinary System Disease, also referred to as urologic disease, encompasses disorders of the bladder and kidneys, characterized by symptoms such as dysuria, polyuria, and urinary urgency. The B2M gene (Beta-2-Microglobulin) is notably associated with this condition, with related biological pathways including Cell differentiation - expanded index and miRNAs involved in DNA damage response. Treatment options may include drugs such as Bupivacaine and Tranexamic acid, and affected tissues primarily include the kidney and prostate.

 

Urologic Disease (18):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-B0662
    Imidafenacin 170105-16-5 99.26%
    Imidafenacin (KRP-197; ONO-8025) is an orally active inhibitor of muscarinic (mAChR) M1 and M3 receptors. Imidafenacin potently inhibits bladder contraction in vivo and exerts an antidiuretic effect by enhancing the signaling pathway of vasopressin (antidiuretic hormone). Imidafenacin can be used in research related to overactive bladder.
    Imidafenacin
  • HY-W008917
    Estrone 3-glucuronide sodium 15087-01-1 98.78%
    Estrone 3-glucuronide sodium is a metabolite of 17-Estradiol.
    Estrone 3-glucuronide sodium
  • HY-W088011B
    Sodium glycolate, 98% 2836-32-0 98.0%
    Sodium glycolate, 98% (Sodium hydroxyacetate, 98%) is an orally active, versatile organic salt. Sodium glycolate, 98% acts as an enzyme activity regulator that increases the activities of glycolate oxidase (GAO) and lactate dehydrogenase (LDH), while reducing the activity of glycolate dehydrogenase (GAD). Sodium glycolate, 98% induces oxalate biosynthesis and causes hyperoxaluria in rats. Sodium glycolate, 98% reduces urinary calcium excretion in male albino rats. Sodium glycolate, 98% can be used in studies related to calcium oxalate urolithiasis and hyperoxaluria.
    Sodium glycolate, 98%
  • HY-14825A
    Tarafenacin D-tartrate 1159101-48-0 99.86%
    Tarafenacin (SVT-40776) (D-tartrate) is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin (D-tartrate) does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin (D-tartrate) can be used in the research of overactive bladder.
    Tarafenacin D-tartrate
  • HY-14825
    Tarafenacin 385367-47-5
    Tarafenacin (SVT-40776) is an orally active, selective M3 muscarinic receptor (M3 muscarinic receptor) antagonist with 203-fold selectivity over the M2 muscarinic receptor. Tarafenacin does not affect atrial contraction, arterial blood pressure or arterial pressure at high doses. Tarafenacin can be used in the research of overactive bladder.
    Tarafenacin
  • HY-Y1150
    Pivalic acid 75-98-9 99.93%
    Pivalic acid (Trimethylmethanecarboxylic acid) is a carboxylic acid. Pivalic acid induces Carnitine deficiency. Pivalic acid conjugated with Antibiotics, such as Pivmecillinam (HY-B0810) and Pivampicillin (HY-119011), are used in urinary tract infection. Pivalic acid can be used in physical exercise research.
    Pivalic acid
  • HY-182715
    PSB-10211 66295-57-6
    PSB-10211 is a P2X2 receptor antagonist with an IC50 of 0.086 μM against rat P2X2 receptors. PSB-10211 inhibits ATP-mediated currents of rat P2X2 receptors expressed in Xenopus oocytes. PSB-10211 can be used in studies related to pain and urinary incontinence.
    PSB-10211
  • HY-118605
    Aminometradine 642-44-4
    Aminometradine is an orally active diuretic. Aminometradine increases urine volume and the excretion of sodium and chloride. Aminometradine can be used in studies of congestive heart failure.
    Aminometradine
  • HY-P991022
    Ruxoprubart 2842046-67-5
    Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy.
    Ruxoprubart
  • HY-121667
    Scaff10-8 777857-56-4 99.11%
    Scaff10-8 is a RhoA inhibitor. Scaff10-8 binds to RhoA, inhibits AKAP-Lbc-mediated RhoA activation. Scaff10-8 can be used for research on diabetes insipidus and bipolar disorder.
    Scaff10-8
  • HY-126941
    Hecogenin acetate 915-35-5 98.57%
    Hecogenin acetate is an orally active steroid saponin aglycone with extensive biological activities. Hecogenin acetate inhibits the phosphorylation of NF-κB and p38 MAPK signaling pathways, antagonizes TRPA1/TRPM8 channels, inhibits the production of pro-inflammatory cytokines, and has anti-inflammatory and analgesic effects. Hecogenin acetate inhibits the production of ROS and the activation of NLRP3 inflammasome; downregulates the expression of MMP-2, and has neuroprotective and anti-tumor activities. Hecogenin acetate enhances gastric mucosal defense and promotes ulcer healing. Hecogenin acetate can be used in combination with certain antibiotics to regulate bacterial efflux pumps and restore antibiotic sensitivity.
    Hecogenin acetate
  • HY-181452
    1-Arachidoyl-2-hydroxy-sn-glycero-3-PA sodium
    1-Arachidoyl-2-hydroxy-sn-glycero-3-PA sodium (LPA 20:0 sodium) (Compound LPA 20:0/lyso) is a lysophospholipid. 1-Arachidoyl-2-hydroxy-sn-glycero-3-PA sodium is detectable in urine.
    1-Arachidoyl-2-hydroxy-sn-glycero-3-PA sodium
  • HY-P1278B
    GR 64349 acetate
    GR 64349 acetate is a selective neurokinin 2 (NK2) receptor agonist. GR 64349 acetate selectively activates the NK-2 receptor subtype. GR 64349 acetate activates tonic and rhythmic bladder contractions of the micturition reflex. GR 64349 acetate does not inhibit rhythmic bladder contraction activation induced by normal saline. GR 64349 acetate induces inward currents.
    GR 64349 acetate
  • HY-182599
    RCC-36 hydrochloride 129927-37-3
    RCC-36 hydrochloride is an L-type calcium channel inhibitor and competitive muscarinic receptor antagonist. RCC-36 hydrochloride inhibits L-type calcium currents in voltage- and concentration-dependent fashion with no effect on cardiac K+ currents. RCC-36 hydrochloride suppresses maximum acetylcholine-induced contractile responses, inhibits detrusor muscle contractions induced by potassium chloride, calcium chloride, and electric field stimulation, including atropine-resistant contractions. RCC-36 hydrochloride can be used for the research of urinary frequency, urinary incontinence, and bladder overactivity.
    RCC-36 hydrochloride
  • HY-182386
    Triflocin 13422-16-7
    Triflocin is an orally active diuretic and Na+-K+-2Cl− cotransporter inhibitor with an IC50 of 3×10-5 M. Triflocin inhibits the outward basolateral electrogenic Na-(HCO3) n>1 cotransport in the proximal tubule. Triflocin has no tendency to induce hyperglycemia, and its blood glucose-elevating effect is extremely weak, such that an increase in blood glucose levels can only be detected under special conditions such as glucose loading. Triflocin is more prone to induce hypoglycemia.
    Triflocin
  • HY-14767
    Fasobegron 643094-49-9
    Fasobegron is a β3-adrenergic receptor agonist with a human EC50 of 4.8 nM. Fasobegron shows an EC50 of 250 nM for human β1-adrenergic receptors. Fasobegron can be used for the research of overactive bladder.
    Fasobegron
  • HY-129518
    Phenamacide hydrochloride 31031-74-0
    Phenamacide hydrochloride is an anti-spasmodic agent that can be used for the study of urinary incontinence.
    Phenamacide hydrochloride
  • HY-108654
    PSB 0474 917567-60-3
    PSB 0474 (3-phenacyl-UDP) is a UDP (HY-113359) analog and selective P2Y6 receptor agonist, with an EC50 value of 70 nM for the hP2Y6 receptor. PSB 0474 activates Phospholipase C-coupled receptors to increase intracellular inositol phosphate levels. PSB 0474 enhances NO release by upregulating inducible iNOS and induces Apoptosis. PSB 0474 increases micturition frequency in urine of anesthetized rats, without altering bladder contraction amplitude/duration or causing urothelial damage. PSB 0474 can be used in studies related to chronic brain inflammation.
    PSB 0474